# Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

> **NCT03892421** · PHASE1,PHASE2 · COMPLETED · sponsor: **La Raza Medical Center** · enrollment: 22 (actual)

## Conditions studied

- Relapsed Non Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Carboplatin
- **DRUG:** Cytarabine Injection
- **DRUG:** Dexamethasone
- **DRUG:** Filgrastim 0.3 MG/ML

## Key facts

- **NCT ID:** NCT03892421
- **Lead sponsor:** La Raza Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-05
- **Primary completion:** 2021-01-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03892421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03892421, "Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT03892421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*